钱塘加速打造人工智能制造和融合创新高地

Group 1 - The core viewpoint emphasizes the integration of AI technology in the pharmaceutical industry, particularly through the development of medical robots and AI-driven drug research [1][2] - Zhejiang Ganaiwei Medical Technology Co., Ltd. is breaking the monopoly of foreign brands in the medical robotics sector with its self-developed CT puncture positioning navigation surgical robot [1] - The Qiantang District aims to leverage AI as a driving force to cultivate key sectors such as AI medicine, embodied intelligence, high-end chips, and smart terminals, promoting AI empowerment across various industries [1][3] Group 2 - The establishment of the "New Drug Creation Concept Verification Center" in Qiantang District, in collaboration with Zhejiang University, has become a preferred location for AI concept validation among biopharmaceutical companies [2] - AI is significantly enhancing drug discovery processes, including target identification and compound design, thereby improving the success rate and effectiveness of molecular generation [2] - Qiantang District is focusing on deep integration of technological and industrial innovation, with a strong emphasis on synthetic biology and the metaverse as future industry pilot zones [2][3] Group 3 - The district is committed to seizing historical opportunities in AI development, aiming to become a benchmark in the collaborative development of "AI + drug research" and "AI + manufacturing" [3] - Qiantang District is actively working to strengthen its future industry pilot zones, including synthetic biology and low-altitude economy, while striving to create national-level future industry pilot zones [3]